Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 2, 2010, Pages 315-323

  Todorova, Valentina K ^a   Kaufmann, Yihong ^c   Hennings, Leah J ^b   Klimberg, V Suzanne ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Cardiotoxicity; Doxorubicin; Glutamine; Plasma cardiac troponin I; Thrombocytopenia; Von Willebrand factor

Indexed keywords

DOXORUBICIN; GLUTAMINE; TROPONIN; TROPONIN I; TROPONIN T; VON WILLEBRAND FACTOR; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BREAST TUMOR; CONTROLLED STUDY; DIET THERAPY; ECHOCARDIOGRAPHY; EDEMA; FEMALE; FLUORESCENCE; HEART; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HEART RATE; HEART VOLUME; IMMUNOHISTOCHEMISTRY; KIDNEY; LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; ECHOGRAPHY; EXPERIMENTAL NEOPLASM; FISCHER 344 RAT; HEART DISEASE; HEART FUNCTION TEST; HEART MUSCLE; METABOLISM; THROMBOCYTOPENIA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; GLUTAMINE; HEART; HEART DISEASES; HEART FUNCTION TESTS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MYOCARDIUM; RATS; RATS, INBRED F344; THROMBOCYTOPENIA; TROPONIN; VON WILLEBRAND FACTOR;

EID: 77953059515     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1165-8     Document Type: Article

References (68)

1. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905
2. Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS (2004) Cardiovascular complications of cancer therapy diagnosis, pathogenesis and management. Circulation 109:3122
3. Doroshow JH (1991) Doxorubicin-induced cardiac toxicity. N Engl J Med 324:843-845
4. Singal PK, Deally CM, Weinberg LE (1987) Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 19:817-828
5. Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4:3076-3086
6. Yi X, Bekeredjian R, DeFilippis NJ, Siddiquee Z, Fernandez E, Shohet RV (2006) Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 290(3):H1098-H1102
7. Olson RD, Boerth RC, Gerber J, Nies AS (1981) Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 29:1393
8. Mihm MJ, Yu F, Weinstein DM, Reiser PJ, Bauer JA (2002) Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Br J Pharmacol 135:581-588
9. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165-167
10. L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W, VanderHeide R (2006) DNA damage is an early event in doxorubicin- induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 291(3):H1273-H1280
11. Jaakkola K, Lahteenmaki P, Laakso J, Harju E, Tykka H, Mahlberg K (1992) Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer Res 12:599-606
12. Singh DK, Lippman SM (1998) Cancer chemoprevention part 1: retinoids and carotenoids and other classic antioxidants. Oncology 12:1643-1660
13. Mimnaugh EG, Kenedy KA, Trush MT, Sinha BK (1985) Adriamycin enhanced membrane lipid peroxidation in isolated rat nuclei. Cancer Res 45:3296-3304
14. Roth E (2008) Nonnutritive effects of glutamine. J Nutr 138:2025S-2031S
15. Lacey J, Wilmore D (1990) Is glutamine a conditionally essential amino acid? Nutr Rev 48:297-309
16. Muhlbacher F, Kapadia CR, Colpoys MF, Smith RJ, Wilmore DW (1982) Alterations in glutamine metabolism in response to operative stress and food deprivation. Surg Forum 33:19-21
17. Oehler R, Roth E (2003) Regulative capacity of glutamine. Curr Opin Clin Nutr Metab Care 6:277-282
18. Bongers T, Griffiths RD, McArdle A (2007) Exogenous glutamine: the clinical evidence. Crit Care Med 35(9 Suppl):S545-S552
19. Tjader I, Berg A, Wernerman J (2007) Exogenous glutamine-compensating a shortage? Crit Care Med 35(9 Suppl):S553-S556
20. Sacks GS (1999) Glutamine supplementation in catabolic patients. Ann Pharmacother 33:348-354
21. Labow BI, Souba WW (2000) Glutamine. World J Surg 24:1503-1513
22. Welbourne T (1979) Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can J Biochem 57:233-237
23. Cao Y, Kennedy R, Klimberg VS (1999) Glutamine protects against doxorubicin-induced cardiotoxicity. J Surg Res 85(1):178-182
24. Carlsson G, Gullberg B, Hafstrom L (1983) Estimation of liver tumor volume using different formulas-an experimental study in rats. J Cancer Res Clin Oncol 105:20-23
25. Bachur NR, Moore AL, Bernstein JG, Liu A (1970) Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods. Cancer Chemother Rep 54:89-94
26. Wurz GT, Soc L, Emshoff VD, Cadman TB, DeGregorio MW (1998) Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin. Cancer Chemother Pharmacol 42(5):363-366
27. Mross K, Maessen P, van der Vijgh WJF, Gall H, Boven E, Pinedo HM (1988) Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6:517-526
28. Wu AH, Ford L (1999) Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis? Clin Chim Acta 284:161-174
29. Palmer BS, Klawitter PF, Reiser PJ, Angelos MG (2004) Degradation of rat cardiac troponin I during ischemia independent of reperfusion. Am J Physiol Heart Circ Physiol 287:H1269-H1275
30. Spiel AO, Gilbert JC, Jilma B (2008) von Willebrand factor in ardiovascular disease: focus on acute coronary syndromes. Circulation 117:1449-1459
31. Fukuchi M, Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K, Yagi T, Iguchi A, Yokoyama H, Miura M, Kagaya Y, Sato S, Tabayashi K, Shirato K (2001) Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 37:1436-1442
32. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA (2003) Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108:2423
33. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M (2008) Biochemical markers for prediction of chemotherapyinduced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 130:688
34. Goorin AM, Borow KM, Goldman A, Williams RG, Henderson IC, Sallan SE, Cohen H, Jaffe N (1981) Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer 47:2810-2816
35. Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M (1985) Doxorubicin-induced congestive heart failure in adults. Cancer 56:1361-1365
36. Unverferth BJ, Magorien RD, Balcerzak SP, Leier CV, Unverferth DV (1983) Early changes in human myocardial nuclei after doxorubicin. Cancer (Phila) 52:215-221
37. Forman DE, Cittadini A, Azhar G, Douglas PS, Wei JY (1997) Cardiac morphology and function in senescent rats: gender-related differences. J Am Coll Cardiol 30:1872-1877
38. Palus S, Akashi Y, von Haehling S, Anker SD, Springer J (2009) The influence of age and sex on disease development in a novel animal model of cardiac cachexia. Int J Cardiol 133:388-393
39. Schwarz ER, Pollick C, Meehan WP, Kloner RA (1998) Evaluation of cardiac structures and function in small experimental animals: transthoracic, transesophageal, and intraventricular echocardiography to assess contractile function in rat heart. Basic Res Cardiol 93:477-486
40. Chen X, Chen Y, Bi Y, Fu N, Shan C, Wang S, Aslam S, Wang PW, Xu J (2007) Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Cardiovasc Drugs Ther 21:367-374
41. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz PE, Berger HJ, Setaro J, Surkin L (1987) Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med 82:1109-1118
42. Weiss HJ (1991) von Willebrand factor and platelet function. Ann NY Acad Sci 614:125
43. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP (1998) Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French investigators of the ESSENCE Trial. Circulation 98:294-299
44. Boerma M, Kruse JJ, van Loenen M, Klein HR, Bart CI, Zurcher C, Wondergem J (2004) Increased deposition of von Willebrand factor in the rat heart after local ionizing irradiation. Strahlenther Onkol 180:109-116
45. Xu MF, Tang PL, Qian ZM, Ashraf M (2001) Effects by doxorubicin on the myocardium are mediated by oxygen free radicals.Life Sci 68:889-901
46. Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65:128-135
47. Abou-El-Hassan MA, Rabelink MJ, van der Vijgh WJ, Bast A, Hoeben RC (2003) A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro. Br J Cancer 89:2140-2146
48. Hershman DL, Shao T (2009) Anthracycline cardiotoxicity after breast cancer treatment. Oncology 23:1-15
49. Villani F, Galimberti M, Zunino F, Monti E, Rozza A, Lanza E, Favalli L, Poggi P (1991) Prevention of doxorubicin induced cardiomyopath by reduced glutathione. Cancer Chemother Pharmacol 28:365
50. Cameron E (1991) Protocol for the use of vitamin C in the treatment of cancer. Med Hypothesis 36:190-194
51. Folkers K, Brown R, Judy W, Morita M (1993) Survival of cancer patients on therapy with coenzyme Q10 Bioch. Bioph Res Comm 192:241-245
52. Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, Doroshow J, Epstein SA (1983) A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 10(Suppl 1):53
53. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ, Mitchell RB, Negrin R, Szatrowski TP (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17:3333-3355
54. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey MJ, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, Blum RH, Feit F, Attubato MJ, Burrows W (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127
55. Zima T, Tesar V, Sherwood R, Sood A, Au LC, Richardson PJ, Preedy VR (2001) Acute dosage with dexrazoxane, but not doxorubicin, is associated with increased rates of hepatic protein synthesis in vivo. Toxicol Pathol 29:591-599
56. Khogali SE, Harper AA, Lyall JA, Rennie MJ (1998) Effects of L-glutamine on post-ischaemic cardiac function: protection and rescue. J Mol Cell Cardiol 30:819-827
57. Khogali SE, Pringle SD, Weryk BV, Rennie MJ (2002) Is glutamine beneficial in ischemic heart disease? Nutrition 18:123-126
58. Klimberg V, Nwokedi B, Hutchins L, Pappas AA, Lang NP, Broadwater JR, Read RC, Westbrook KC (1991) Does glutamine facilitate chemotherapy while reducing its toxicity? Surg Forum 42:16-18
59. Todorova VK, Harms SA, Kaufmann Y, Luo S, Luo KQ, Babb K, Klimberg VS (2004) Glutamine supplementation reduces glutathione levels and stimulates apoptosis in DMBA-induced mammary tumors. Breast Cancer Res Treat 88:247-256
60. Klimberg VS (1996) Glutamine, cancer and its therapy. Am J Surg 172:418-424
61. Meister A, Anderson MA (1983) Glutathione. Annu Rev Biochem 52:711
62. Friezen C, Kiess Y, Debatin KM (2004) A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ 11(Suppl. 1):S73-S85
63. Wolf CR, Hayward IP, Lawrie SS, Buckton K, McIntyre MA, Adams DJ, Lewis AD, Scott AR, Smyth JF (1985) Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor response. Proc Am Assoc Cancer Res 26:338
64. Kaufmann Y, Todorova VK, Luo S, Klimberg VS (2008) Effect of dietary glutamine on glutathione recycling in DMBA-breast cancer model. Nutr Cancer 60:518-525
65. Todorova VK, Vanderpool D, Blossom S, Nwokedi E, Schaefer R, Mrak R, Klimberg VS (2009) Oral glutamine protects against cyclophosphamide-induced cardiotoxicity and death through changes in glutathione metabolism. Nutrition 25:812-817
66. Rubio IT, Cao Y, Hutchins LF, Westbrook KC, Klimberg VS (1998) Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg 227:772-778
67. Klimberg VS, Pappas AA, Nwokedi E, Jensen JC, Broadwater JR, Lang NP, Westbrook KC (1992) Effect of supplemental dietary glutamine on methotrexate concentrations in tumors. Arch Surg 127:1317-1320
68. Wischmeyer PE (2008) Glutamine: role in critical illness and ongoing clinical trials. Curr Opin Gastroenterol 24:190-197